Compare BRUN & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRUN | OMER |
|---|---|---|
| Founded | 2023 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2026 | 2008 |
| Metric | BRUN | OMER |
|---|---|---|
| Price | $6.12 | $16.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $42.75 | $27.50 |
| AVG Volume (30 Days) | ★ 4.0M | 1.1M |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $550.82 | N/A |
| Revenue Next Year | $214.84 | $73.59 |
| P/E Ratio | ★ N/A | $23.61 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.62 | $6.24 |
| 52 Week High | $40.46 | $21.24 |
| Indicator | BRUN | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 32.25 | 43.25 |
| Support Level | N/A | $16.17 |
| Resistance Level | $26.68 | $19.68 |
| Average True Range (ATR) | 0.82 | 0.83 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 17.89 | 23.34 |
Boost Run Inc is an NVIDIA Cloud Provider. Its platform provides GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. Enterprises rely on Boost Run to power their main demanding AI workloads with the performance, security, and reliability their operations require. The group maintains SOC 2 Type II, HIPAA, ISO 27001, and ISO 27701 certifications at the operator level, and partners with data center facilities that uphold equivalent security and compliance standards.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.